MDL | MFCD21609265 |
---|---|
Molecular Weight | 580.74 |
Molecular Formula | C29H40N8O3S |
SMILES | COC(C=C(N1CCC(N2CCN(C)CC2)CC1)C=C3)=C3NC4=NC=NC(NC5=C(S(C(C)C)(=O)=O)C=CC=C5)=N4 |
ASP3026 is a potent, selective and orally active inhibitor of anaplastic lymphoma kinase (ALK) . ASP3026 induces apoptosis of tumor cells. ASP3026 can be used for the research of non-small cell lung cancer (NSCLC) [1] [2] .
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT01401504 | Astellas Pharma Inc |
Solid Tumor
|
May 2011 | Phase 1 |
NCT01284192 | Astellas Pharma Inc |
Advanced Malignancies|Positive for Anaplastic Lymphoma Kinase|Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS|Solid Tumor|B-Cell Lymphoma
|
December 2010 | Phase 1 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 20 mg/mL ( 34.44 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 1.7219 mL | 8.6097 mL | 17.2194 mL |
5 mM | 0.3444 mL | 1.7219 mL | 3.4439 mL |
10 mM | 0.1722 mL | 0.8610 mL | 1.7219 mL |